Offspring number, pregnancy, and risk of a first clinical demyelinating event the AusImmune Study

A Ponsonby, R Lucas, I van der Mei, K Dear, Patricia Valery, M Pender, B Taylor, T Kilpatrick, A Coulthard, C CHAPMAN, D WILLIAMS, A McMichael, T Dwyer

Research output: Contribution to journalArticlepeer-review


Objective: To examine the association between past pregnancy, offspring number, and first clinical demyelination risk.

Methods: Cases (n = 282) were aged 18–59 years with a first clinical diagnosis of CNS demyelination (first clinical demyelinating event [FCD]) and resident within 1 of 4 Australian centers (from latitudes 27° south to 43° south) from 2003 to 2006. Controls (n = 542) were matched to cases on age, sex, and study region, without first clinical diagnosis of CNS demyelination.

Results: Higher offspring number was associated with FCD risk among women (p < 0.001) but not men (p = 0.71); difference in effect; p = 0.001. Among women, higher parity was associated with reduced risk of FCD (adjusted odds ratio 0.51 [95% confidence interval 0.36, 0.72] per birth) with a similar magnitude of effect observed among classic first demyelinating events (adjusted odds ratio 0.47 [95% confidence interval 0.29, 0.74]). The apparent beneficial effect of higher parity was also evident among parous women only (p < 0.001). Among cases, a clear female excess was evident for those with low but not high (4 or more) offspring number. Factors such as human leukocyte antigen DR15 genotype did not appear to modify the association between higher parity and a reduced FCD risk among women.

Conclusions: These findings are consistent with a cumulative beneficial effect of pregnancy. Temporal changes toward an older maternal age of parturition and reduced offspring number may partly underlie the increasing female excess among MS cases over time.

Original languageEnglish
Pages (from-to)867-874
Number of pages8
Issue number12
Publication statusPublished - 20 Mar 2012


Dive into the research topics of 'Offspring number, pregnancy, and risk of a first clinical demyelinating event the AusImmune Study'. Together they form a unique fingerprint.

Cite this